Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials.
Yan JiVitaly YartsevMichelle QuinlanPaolo SerraYingbo WangAbhijit ChakrabortyMichelle MillerPublished in: Clinical pharmacokinetics (2023)
Clinicaltrials.gov identifiers: NCT02431481, NCT01958021, NCT02422615, NCT02278120, NCT01237236, NCT01898845, NCT01872260.